[CAS NO. 1644545-52-7] Vorasidenib (AG-881)
Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis, please:
PRODUCTS SPECIFICATIONS [1644545-52-7]
Store
Catalog
SLK-S8611
Brand
Selleck
CAS
1644545-52-7
DESCRIPTION [1644545-52-7]
Overview
| MDL | MFCD31630835 |
|---|---|
| Molecular Weight | 414.74 |
| Molecular Formula | C14H13ClF6N6 |
| SMILES | C[C@@H](NC1=NC(C2=NC(Cl)=CC=C2)=NC(N[C@H](C)C(F)(F)F)=N1)C(F)(F)F |
For research use only.
Storage
3 years,-20°C,powder
1 years,-80°C,in solvent
1 years,-80°C,in solvent
Shipping
Room temperature shipping(Stability testing shows this product can be shipped without any cooling measures.)
Preparing Stock Solutions
| 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4111 mL | 12.0557 mL | 24.1115 mL |
| 5 mM | 0.4822 mL | 2.4111 mL | 4.8223 mL |
| 10 mM | 0.2411 mL | 1.2056 mL | 2.4111 mL |
| 50 mM | 0.0482 mL | 0.2411 mL | 0.4822 mL |
Description
Vorasidenib (AG-881) is an orally available inhibitor of mutated forms of both .
In vitro
Pan-IDH1/2 inhibitor (AG881) selectively inhibit mutant IDH protein and induce cell differentiation in in vitro and in vivo models. Upon administration, pan-IDH mutant inhibitor AG-881 specifically inhibits mutant forms of IDH1 and IDH2, thereby inhibiting the formation of the oncometabolite 2-hydroxyglutarate (2HG) from alpha-ketoglutarate (a-KG). This prevents 2HG-mediated signaling and leads to both an induction of cellular differentiation and an inhibition of cellular proliferation in tumor cells expressing IDH mutations.
In vivo
AG-881 fully penetrates the blood-brain barrier. AG-881 has been developed and is in early phase I testing for patients with IDH mutation-positive hematologic malignancies and solid tumors, including glioma.
References
Powered by Arctom Copyright © 2026 Arctom. All rights
reserved.